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Background: Vascular endothelial zinc ﬁnger 1 (Vezf1) is a transcription factor previously shown to regulate
vasculogenesis and angiogenesis. We aimed to investigate the role of Vezf1 in the postnatal heart.
Methods: The role of Vezf1 in regulating cardiac growth and contractile function was studied in zebraﬁsh and
in primary cardiomyocytes.
Findings: We ﬁnd that expression of Vezf1 is decreased in diseased human myocardium and mouse hearts.
Our experimental data shows that knockdown of zebraﬁsh Vezf1 reduces cardiac growth and results in
impaired ventricular contractile response to b-adrenergic stimuli. However, Vezf1 knockdown is not associ-
ated with dysregulation of cardiomyocyte Ca2+ transient kinetics. Gene ontology enrichment analysis indi-
cates that Vezf1 regulates cardiac muscle contraction and dilated cardiomyopathy related genes and we
identify cardiomyocyte Myh7/b-MHC as key target for Vezf1. We further identify a key role for an MCAT
binding site in the Myh7 promoter regulating the response to Vezf1 knockdown and show that TEAD-1 is a
binding partner of Vezf1.
Interpretation: We demonstrate a role for Vezf1 in regulation of compensatory cardiac growth and cardio-
myocyte contractile function, which may be relevant in human cardiac disease.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Cardiovascular diseases are a global health problem and the leading
cause of death in the Western world [1]. Sustained increase in cardiac
workload, due to cardiovascular pathologies such as systemic hyper-
tension, myocardial infarction (MI) and valvular heart disease, induces
cardiac hypertrophy as an adaptive response allowing the heart to
maintain cardiac output. Prolonged cardiac hypertrophy, however,
predisposes to heart failure, which is characterized by diverse cellular
abnormalities in the myocardium, including suppressed angiogenesis,
vascular rarefaction, and aberrant Ca2+ cycling, eventually culminating
in decreased left ventricular (LV) function [2,3].Transcription factors, such as GATA-4, NKX2.5 and myocyte
enhancer factor 2 (MEF2) have been shown to be nodal for cardiovas-
cular development and later identiﬁed to play a role in the postnatal
heart [4,5]. GATA-4, for example, is highly expressed during develop-
ment and reactivated during cardiac pathologies regulating both endo-
thelial cell and cardiomyocyte function [6,7]. A gene trap screen for
early cardiovascular genes has previously identiﬁed a zinc ﬁnger tran-
scription factor, Vezf1 [8]. Vezf1 encodes a nuclear protein containing
six zinc ﬁnger motifs of the C2H2-type (kr€uppel-like) and a proline-
rich transcriptional transactivation domain and it is highly conserved
among vertebrates. In embryos, according to its name, Vezf1 has been
shown to be expressed in endothelial cells as well as in mesodermal
and neuronal tissues [9,10]. In one study, Vezf1 expression has also
been detected in various adult human tissues, including the heart [8].
Human Vezf1 (also known as ZNF161 or DB1) functions as a bona ﬁde
transcription factor activating the endothelin-1 promoter [11].
Research in context
Evidence before this study
Transcription factor Vezf1 has been shown to play an important
role in angiogenesis and lymphangiogenesis especially during
embryonic development.
Added value of this study
In our study, we ﬁnd that Vezf1 is necessary for hemodynamic
stress-induced increase in cardiac growth and contractile func-
tion. Vezf1 is expressed in adult cardiomyocytes, binds tran-
scription factor TEAD-1 and directly regulates expression of
cardiomyopathy related genes.
Implications of the available evidence
Our data indicates a novel role for Vezf1 in regulating cardiac
structure and function and provides a potential therapeutic tar-
get for alleviating development of heart failure.
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mediated transcription [12]. A role for Vezf1 in epigenetic gene regula-
tion has also been suggested [13]. Vezf1-null mice are embryonic
lethal, the main defects being in the vascular endothelium [9]. In a
genome-wide quantitative trait loci mapping in zebraﬁsh, Vezf1 was
identiﬁed as a candidate gene causing genetic susceptibility to cardio-
toxicity induced by dioxin-like compounds, suggesting a role for Vezf1
in the vertebrate heart [14]. The Vezf1 gene is located in the long arm
of chromosome 17. Deletions in this area (17q2117q24) have been
reported to result in growth retardation, global developmental delay
and speciﬁc musculoskeletal defects including congenital heart disease
[15]. Overall, Vezf1 is poorly characterized and its possible role in the
postnatal heart remains to be determined.
Zebraﬁsh (Danio rerio) is a powerful model for studying the
molecular and cellular mechanisms of cardiovascular diseases, as
these are highly similar between zebraﬁsh and other vertebrates
[16]. Here we set out to investigate the role of Vezf1 in healthy and
stressed myocardium. We ﬁnd that Vezf1 gene expression is
decreased in diseased human myocardium and in mouse hearts sub-
jected to MI. Our experimental data shows that Vezf1 is required for
normal and b-adrenergic stimuli-induced cardiac growth. Vezf1
knockdown in zebraﬁsh blunts the b-adrenergic stress-induced
increase in cardiac contractile function, which is not due to impaired
Ca2+ cycling. Instead, we ﬁnd that Vezf1 is expressed in adult cardio-
myocytes and directly regulates genes related to cardiac muscle con-
traction and dilated cardiomyopathy. We further demonstrate that
Vezf1 interacts with transcriptional enhancer factor-1 (TEF-1/TEAD-
1), and regulates b-myosin heavy chain (b-MHC/Myh7) expression at
least partially via an MCAT binding site in the b-MHC promoter. Our
data thus identiﬁes Vezf1 as a novel transcription factor necessary for
b-adrenergic stress-induced increase in cardiac growth and contrac-
tile function.
2. Materials and methods
2.1. Human cardiac samples
The human MI samples were obtained from the Fingesture study,
which has stored both clinical and autopsy data from sudden cardiac
death (SCD) victims between 1998 and 2018 in Northern Finland
(n = 4031) [17]. The study complies with the Declaration of Helsinki
and was approved by the Ethics Committee of the Northern Ostro-
bothnia Hospital District. The National Authority for MedicolegalAffairs (Valvira) approved the review of postmortem data by the
investigators. All victims were autopsied at the Department of Foren-
sic Medicine, University of Oulu, Oulu, Finland and subjects with a
history and ﬁndings of diseased coronary arteries at autopsy were
considered cases with coronary artery disease. Samples of healthy
cardiac tissue were collected from autopsies of trafﬁc accident vic-
tims with no evidence of cardiovascular disease. Heart failure -related
datasets GSE5406 and GSE1145 were obtained from the Gene Expres-
sion Omnibus database.
2.2. Zebraﬁsh
Larvae of the wild-type Turku strain of zebraﬁsh [18,19] were
maintained and bred according to Westerﬁeld [20] at the Biomedicum
Helsinki Zebraﬁsh Unit. 24 days post fertilization (dpf) zebraﬁsh
were used for the experiments. Zebraﬁsh larvae were maintained in
E3 medium (5.0 mM NaCl, 0.4 mM CaCl2, 0.3 mM MgSO4 and 0.2 mM
KCl) and treated with isoprenaline (Iso) (Sigma-Aldrich, St. Louis, MO)
when desired. For heart resection, zebraﬁsh were anesthetized in
0.03% tricaine. Zebraﬁsh without heart resection were euthanized in
0.03% tricaine followed by addition of ice. Experiments on zebraﬁsh
were performed in accordance with protocols approved by the
National Animal Experiment Board of Finland (ESAVI/4131/04.10.07/
2017). Vezf1 splice-blocking morpholino antisense oligonucleotides
(SBMO) 5-CATTGGCCTGCTGGATGGAGAAAGA-3, Vezf1 translation-
blocking MO (TBMO) 5-ATGAACTCCAGCTCGGCTCCATTGC-3and ran-
dom control oligo (control) 25-N were from Gene Tools, LLC (Philo-
math, OR). Dosage was determined by titration; 34 ng for SBMO and
57 ng for TBMO. After conﬁrming similar ﬁndings with bothmorpho-
linos in phenotype as well as in cardiac physiology, experiments were
done with SBMOs, as they better allowed simultaneous qPCR experi-
ments. For the rescue experiments 250 pg of capped Vezf1 mRNA was
co-injected with SBMO.
2.3. TUNEL
Zebraﬁsh hearts at 4 dpf were dissected, ﬁxed in 4% paraformalde-
hyde (PFA) and washed two times in PBS. The samples were stained
with ApopTag Red In Situ Apoptosis Detection Kit (Millipore, Burling-
ton, MA), Mef-2 antibody (SC-313, RRID: AB_631,920, Santa Cruz Bio-
technology, Dallas, TX) and Dapi (Thermo Fisher Scientiﬁc, Waltham,
MA). Anti-rabbit Alexa Fluor 488 antibody (A-11,008, RRID:
AB_143,165, Thermo Fisher Scientiﬁc) was used as secondary anti-
body. Images were obtained with a Zeiss Apotome (Carl Zeiss Micros-
copy GmbH, Jena, Germany) equipped with a Hamamatsu ORCA-R2
camera (Hamamatsu Photonics, Shizuoka, Japan) and quantiﬁed with
ImageJ 1.43 u software (RRID: SCR_003070, NIH, Bethesda, MD).
2.4. Ventricular cardiomyocyte size and number
Hearts were dissected from 4 dpf zebraﬁsh larvae and ﬁxed in 4%
PFA and washed in PBS + 0,1% Triton. Hearts were stained with Mef-2
(SC-313, RRID: AB_631,920) and ZN-5 (RRID: AB_10,013,770, Zebra-
ﬁsh International Resource Center) antibodies overnight at +4 °C.
Anti-rabbit Alexa Fluor 594 (A-11,012, RRID: AB_141,359) and anti-
mouse Alexa Fluor 488 (A-11,001, RRID: AB_2,534,069, Thermo
Fisher Scientiﬁc) were used as secondary antibodies. Images were
captured with a Zeiss AxioImager Z1 microscope by using a Hama-
matsu ORCA-R2 camera. Images were analyzed using ImageJ as fol-
lows: both anterior and posterior walls were divided to four roughly
equal size sectors and the size of four randomly selected cardiomyo-
cytes from each sector was measured and the average cardiomyocyte
area of the 32 cardiomyocytes was measured. The total number of
cardiomyocytes was counted using the ImageJ Plugin Extended
Depth of Field.
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Whole zebraﬁsh were ﬁxed in 1% glutaraldehyde and 4% formalde-
hyde in 0.1 M phosphate buffer, postﬁxed in 1% osmium tetroxide,
dehydrated in acetone and embedded in Epon LX 112 (Ladd Research
Industries). Thin sections were cut with a Leica Ultracut UCT ultrami-
crotome, stained in uranyl acetate and lead citrate and examined in a
Philips CM100 transmission electronmicroscope. The images were cap-
tured using a Morada CCD camera (Olympus Soft Imaging Solutions).
2.6. Cardiac physiology and vasculature
The heart function of 2 dpf and 4 dpf larvae was recorded and ana-
lyzed from the recorded videos as described earlier [21]. Brieﬂy, lar-
vae were anesthetized in 0.008% tricaine solution and mounted on
3% methylcellulose. Heart and vascular videos were recorded with an
Olympus IX70 microscope (Olympus, Tokyo, Japan), a Hamamatsu
ORCA-Flash 4.0 camera and HCImage software (RRID:SCR_015041,
Hamamatsu Photonics, Shizuoka, Japan) and analyzed with ImageJ.
Diameters and distances of vascular structures were measured from
the zebraﬁsh trunk from the area where the dorsal aorta (DA) and
the posterior cardinal vein (PCV) are parallel. The distance between
intersegmental vessels (ISVs) was measured from 35 locations of
the zebraﬁsh trunk, and the average calculated.
2.7. Ca2+ cycling in zebraﬁsh hearts
For Ca2+ imaging, hearts from 3 dpf larvae were loaded with
55mM Fura2 (Thermo Fisher Scientiﬁc) for 30 min and then de-ester-
iﬁed for 20 min as described [21]. The hearts were perfused with
Tyrode’s solution and paced with 10 ms bipolar pulses at 1.25 Hz by
using a SIU-102 Stimulus Isolation Unit (Warner Instruments, Ham-
den, CT). Images were recorded with a Hamamatsu ORCA-Flash 4.0
camera at 1024 frames per second. Polychrome IV (Till Photonics,
Gr€afelﬁng, Germany) was used as the light source. The ventricle was
selected as region of interest and background ﬂuorescence was sub-
tracted before quantifying the ﬂuorescence in relation to baseline
ﬂuorescence (F/F0). Resting Ca2+ concentration and Ca2+ transient
amplitude are presented as Fura2 340/380 ratio units. Data were ana-
lyzed with HCImage and Axon Clampﬁt 9.2 (Molecular Devices, San
Jose, CA) softwares. Only hearts that appeared unharmed after isola-
tion and showed spontaneous beating with normal atrioventricular
conduction were included in the analyses.
2.8. Neonatal rat ventricular cardiomyocytes
Neonatal rat ventricular cardiomyocytes (NRVMs) were isolated
from 2 to 4-day old Sprague-Dawley (SD) rats. Rats were euthanized
by quick decapitation and ventricles were collected into 2 mg/ml col-
lagenase type 2 solution (Worthington, Lakewood, NJ) prepared in
1xPBS with 50 mM CaCl2. The heart fragments were incubated for
5 min at +37 °C with stirring, and thereafter the collagenase solution
was discarded. 5 ml of collagenase solution was added and incubated
for 20 min at +37 °C with stirring and the collagenase solution was
collected through 100 mm nylon cell strainer (BD, Franklin Lakes, NJ)
to DMEM/F-12 (Sigma-Aldrich) containing 30% fetal bovine serum
(Thermo Fisher Scientiﬁc) and 1% penicillin-streptomycin (PS). This
process was repeated 5 times. The cells were next pelleted (200 g,
5 min) and washed with DMEM/F-12 supplemented with 10% FBS
and 1% PS. To reduce the number of contaminating non-muscle cells,
the cells were pre-plated onto culture dishes (BD) for 2 h at 37 °C in
humidiﬁed atmosphere with 5% CO2. Isolated NRVMs were plated
and incubated in DMEM/F-12 supplemented with 10% FBS and 1% PS
overnight. siRNA transfections were performed one day after cell iso-
lation and experiments were started 24 days after transfection. For
hypoxia experiments, four days after siRNA transfections cells wereincubated in DMEM supplemented with 10 mM deoxyglucose and
1 mM sodium dithionite (Honeywell-Fluka, Morris Plains, NJ), and
kept in a C-Chamber (BioSpherix, Parish, NY) and oxygen levels con-
trolled at 0.1% with a ProOx C21 controller (BioSpherix). Control (nor-
moxia) cells were incubated in DMEM (Thermo Fisher Scientiﬁc)
supplemented with 10 mM glucose.
2.9. Adult ventricular cardiomyocytes
Mouse ventricular cardiomyocytes, cardiac endothelial cells and
ﬁbroblasts were isolated from 8-week old c57/BL6 mice as described
previously [22]. Adult rat ventricular cardiomyocytes (ARVMs) were
isolated from 812 weeks old male SD rats by retrograde perfusion
and enzymatic digestion using collagenase type 2 (Worthington) as
previously described [23]. After 2 h incubation, non-attached cells
were gently removed and cells were transfected with desired siRNAs.
Experiments were started 2448 h after transfection. Ca2+ transients
from cultured ARVMs were measured as previously described [24]. For
measurement of adult rat cardiomyocyte size, isolated ARVMs were
plated on laminin coated glass chamber slides and treated with iso-
prenaline (1 mM) when appropriate. For measurement of cardiomyo-
cyte size, cells were ﬁxed with 4% paraformaldehyde, blocked with
10% FBS in PBS and stained with Alexa Fluor 488 Phalloidin (Thermo
Fisher Scientiﬁc). The cells were viewed with a Nikon Eclipse 80i
microscope (Nikon, Tokyo, Japan), and captured with an ORCA-Flash
4.0 camera and NIS-Elements AR 4.30.01 software (RRID: SCR_014329,
Nikon). Only rod-shaped cardiomyocytes were measured.
2.10. RNA interference
Speciﬁc Vezf1 siRNAs (Vezf1A 50-CCCAAAACUUCGUUUGUGUtt-30
and Vezf1B 50-GGUAUCAUGUAACAUCUGUtt-30), Tead1 siRNAs
(Tead1A 50-AGACGGAGUAUGCGAGGUUUU-30 and Tead1B 50-
GAGUAUGCGAGGUUCGAGAUU-30) and negative control siRNA
(SIC001, Sigma-Aldrich) were transfected into the NRVMs and ARVMs
at 100 nM concentration by using Lipofectamine 2000 (Thermo Fisher
Scientiﬁc) as transfection reagent. During transfections NRVMs were
incubated in Opti-MEM I (Thermo Fisher Scientiﬁc) for 24 h and
thereafter the cells were incubated in serum free medium. ARVMs
were transfected for 18 h and thereafter incubated in aMEM (Thermo
Fisher Scientiﬁc) supplemented with Earle’s salt containing 0.01% BSA,
10 mMHEPES, 1 £ insulin-transferrin-selenium, 10 mM BDM, 2 mM L-
glutamine and 1% PS.
2.11. Plasmids
b-MHC promoter luciferase reporter constructs were a kind gift
from Fadia Haddad and are previously described [5]. The activities of
b-MHC promoter luciferase reporter and Renilla luciferase pRL-TK
were analyzed using Dual-luciferase Reporter Assay System (Promega,
Madison, WI) 48 h after transfection. For Vezf1 expression plasmid,
coding sequence of mouse Vezf1 (NM_016686.4) was cloned into
pcDNA3.1 vector using BamHI cloning site. An empty pcDNA3.1 vector
was used as control. Plasmids were transfected into the NRVMs and
ARVMs using Lipofectamine 2000 as transfection reagent.
2.12. RNA isolation, cDNA synthesis and qRT-PCR analysis
Trizol (Thermo Fisher Scientiﬁc) was used for isolation of RNA from
human cardiac tissue samples and an EZNA Total RNA kit I (Omega
Bio-tek, Norcross, GA) from isolated cardiomyocytes and from crushed
zebraﬁsh larvae. Nuclease-Free water (Thermo Fisher Scientiﬁc) was
used to dissolve the RNA pellets or eluate the RNA from isolation col-
umns when using the EZNA kit. For cDNA synthesis Transcriptor ﬁrst
strand cDNA synthesis kit (Roche, Basel, Switzerland) was used accord-
ing to manufacturer’s instructions. The relative mRNA levels were
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probes, the qRT-PCR reaction mixtures contained 1 ml of the ﬂuoro-
genic probe (Sigma-Aldrich), 2.5 ml of each forward and reverse
primer (5 mM stock, Sigma-Aldrich), 2 ml of nuclease-free water
(Thermo Fisher Scientiﬁc) and 12.5 ml of Fast Start Universal Probe
Master (Roche). When using SYBR reagent, the qRT-PCR reaction mix-
tures contained 2.5 ml of each forward and reverse primer, 2.5 ml of
nuclease-free water (2 mM stock, Thermo Fisher Scientiﬁc) and
12.5 ml of SYBR Green PCR Master Mix (Thermo Fisher Scientiﬁc). For
the qRT-PCR-plate, 20 ml of the qRT-PCR reaction mix was added
together with 5 ml of template cDNA. The sequences of the forward
and reverse primers and the ﬂuorogenic probes used for gene-speciﬁc
cDNA detection are listed in Table S1. The qRT-PCR analyses were
done with a 7300 Real Time PCR System (Thermo Fisher Scientiﬁc).
2.13. Protein isolation, immunoprecipitation and immunoblotting
Rat cardiac cells and rat left ventricular tissue samples were lysed
into 20 mM TrisHCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Tri-
ton-X100, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate
and 1 mMNa3VO4 (pH 7.5) supplemented with 1 mM 1,4-dithiothrei-
tol, 50 mM sodium ﬂuoride, 1:100 protease inhibitor cocktail 1
(Sigma-Aldrich) and 1:100 phosphatase inhibitor cocktail 3 (Sigma-
Aldrich). For immunoprecipitation a Pierce Crosslink IP Kit was used
according to manufacturer’s instructions (Thermo Fisher Scientiﬁc).
250 mg of total protein from rat left ventricular samples was immu-
noprecipitated with 5 mg of Vef1 antibody (RRID: AB_10,606,448,
SAB2102675, Sigma-Aldrich). Cell lysates and immunoprecipitation
eluates were loaded on SDSPAGE (12%) and transferred to nitrocel-
lulose membranes using Trans-Blot TurboTM RTA Transfer Kit (BIO-
RAD, Hercules, CA) together with Trans-Blot TurboTM Transfer Sys-
tem (BIO-RAD) according manufacturer’s instructions. The mem-
branes were then blocked with 1:1 ratio of Odyssey Blocking Buffer
(LI-COR Biosciences, Lincoln, NE) and TBS-Tween buffer (50 mM Tris
base, 200 mM NaCl, 0.05% Tween 20, pH 7.4) for 1 h at room tempera-
ture (RT). Primary antibody incubations were performed in 1:1 ratio
of Odyssey Blocking and TBS-Tween buffer, overnight at +4 °C. Pri-
mary antibodies used were 1:1000 b-MHC (MAB1628, RRID:
AB_2,282,287, Merck, Darmstadt, Germany), 1:1000 skeletal alpha
actin (Ska, ab28052, RRID: AB_867,491, Abcam, Cambridge, United
Kingdom), 1:1000 atrial natriuretic peptide (ANP, custom made),
1:2000 Vinculin (ab18058, RRID: AB_444,215, Abcam), 1:500 TEAD-1
(610,922, RRID: AB_398,237, BD) and 1:1,000,000 glyceraldehyde
3phosphate dehydrogenase (GAPDH, MAB374, RRID: AB_2,107,445,
Millipore). The following day, membranes were washed three times
and incubated with appropriate secondary antibody in 1:1 ratio of
Odyssey Blocking and TBS-Tween buffer for 1 h at RT. The secondary
antibodies used were 1:5000 Alexa Fluor 680 (A21076, RRID:
AB_2,535,736, Thermo Fisher Scientiﬁc) and 1:5000 Alexa Fluor 790
(A11371, RRID: AB_2,534,144, Thermo Fisher Scientiﬁc). Odyssey Fc
Imaging System (LI-COR Biosciences) and Image Studio 4.0 software
were used to visualize the blots.
2.14. RNA sequencing analysis
RNA sequencing of RNA samples from neonatal rat ventricular
cardiomyocytes was performed by the Finnish Microarray and
Sequencing Centre's (Turku centre for Biotechnology, Turku, Finland)
analysis service. All the analyses were performed with R language
and environment for statistical computing version 3.2 (20150416)
and the bioinformatics related Bioconductor module version 3.2.
2.15. Statistical analysis
Data presentations were drawn and statistical analyses were per-
formed using GraphPad Prism6 (California, United States). Data in thegraphs are presented as mean § SD. Normally distributed data was
analyzed with Student’s T-test or in case of multiple groups, with one-
way ANOVA followed by Tukeys post hoc test. If normality was not pos-
sible to verify, data was analyzed with Mann Whitney U test in case of
two groups and with Kruskal-Wallis followed by Dunn’s post hoc test
in case of three or more groups. P< 0.05 was considered signiﬁcant.
3. Results
3.1. Vezf1 expression is decreased in diseased human myocardium
To determine the potential role for Vezf1 in human cardiac dis-
ease, we analyzed two different microarray data sets of human heart
failure samples (accession numbers GSE5406 and GSE1145) compar-
ing healthy donor hearts to ischemic and idiopathic cardiomyopathy
transplantation hearts. We found that Vezf1 expression is decreased
by 20% (P < 0.05) and by 25% (P < 0.01) in idiopathic cardiomyopa-
thy, and by 25% (P< 0.01) and 16% (P = 0.07) in ischemic cardiomyop-
athy compared to the control hearts in GSE5406 and GSE1145,
respectively (Fig. 1A). To conﬁrm the ﬁndings from the microarray
data sets, we analyzed for Vezf1 gene expression in hearts of SCD vic-
tims with ischemic heart disease. Heart samples of age-matched vic-
tims of trafﬁc accidents without a history or post mortem evidence of
cardiovascular disease served as controls. We found that Vezf1
expression is decreased by 43% in hearts of SCD cases with ischemic
heart disease compared to control hearts (Fig. 1B, P < 0.05). We then
analyzed for Vezf1 expression in hearts of mice subjected to experi-
mental heart failure models and found that LV Vezf1 expression is
decreased at 3, 5 and 7 days after MI, but no difference is observed at
5 or 10 weeks after MI (Fig. 1C).
3.2. Vezf1 regulates vasculogenesis and angiogenesis
To investigate the role of Vezf1 in cardiovascular biology, we used
morpholino (MO) antisense oligonucleotides to deplete Vezf1 in zebra-
ﬁsh. Microinjection of zebraﬁsh embryos with SBMO antisense oligo-
nucleotides resulted in 95% decrease in Vezf1 expression at 1 dpf
(p < 0.0001). Molecular mechanisms regulating vessel formation in
zebraﬁsh are highly similar to those in humans and optical transpar-
ency of developing zebraﬁsh allows high-resolution optical imaging of
vascular structures [26]. Analysis of vascular structures in zebraﬁsh at
4 dpf shows that Vezf1 knockdown has no effect on DA and PCV diam-
eter, but reduces the distance between DA and PCV (Fig. 2AD). Vezf1
knockdown also reduces the DA-PCV distance in zebraﬁsh treated
with 300 mM isoprenaline for 48 h (Fig. 2D). Co-injection of zebraﬁsh
with capped Vezf1 mRNA (cRNA) was used in parallel experiments to
rescue Vezf1 expression upon Vezf1 MO-induced Vezf1 knockdown.
As shown in Fig. 2D, Vezf1 rescue with capped Vezf1 mRNA (cRNA)
normalizes the DA-PCV distance in Vezf1 knockdown (KD) zebraﬁsh.
Vezf1 knockdown results in a non-signiﬁcant increase in the distance
between two consecutive ISVs at baseline (Fig. 2F). However, Vezf1
knockdown signiﬁcantly increases ISV  ISV distance in zebraﬁsh sub-
jected to 48 h treatment with isoprenaline, indicating that Vezf1 regu-
lates angiogenesis during b-adrenergic stress. Co-injection of Vezf1
cRNA abrogates the antiangiogenic effect of Vezf1 knockdown
(Fig. 2F), indicating speciﬁcity of the knockdown.
3.3. Vezf1 knockdown reduces cardiac growth
Microscopy analysis of zebraﬁsh at 2 dpf and 4 dpf shows that
Vezf1 knockdown increases pericardial cavity size in non-stressed
hearts (Fig. S1). 48 h isoprenaline treatment from 2 dpf to 4 dpf
increases pericardial cavity size in control zebraﬁsh, and Vezf1 knock-
down results in a signiﬁcant further increase of the pericardial cavity
size (Fig. S1). Pericardiac edema is commonly associated with muta-
tions affecting cardiac function or vascular integrity in zebraﬁsh [16].
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Fig. 1. Vezf1 expression is decreased in diseased human myocardium. (A) Vezf1 expres-
sion in two independent microarray data sets (accession numbers GSE5406 and
GSE1145) comparing RNA samples from healthy human donor hearts (Ctrl) to idiopathic
and ischemic cardiomyopathy transplantation hearts (Idiop. CMP and Isch. CMP, respec-
tively). * indicates FDR adjusted P-value <0.05, ** indicates FDR adjusted P-value <0.01.
(B) qRT-PCR analysis of Vezf1 mRNA levels in healthy control hearts (n = 7) and hearts of
sudden cardiac death victims with ischemic heart disease (MI, n = 20). The results are
shown as relative to Vezf1 mRNA levels in healthy human hearts (Ctrl). (C) Wild type
mice were subjected to myocardial infarction (MI) and RNA was isolated from left ven-
tricular tissue samples 3, 5, 7 days and 5 and 10 weeks later. Shown is qRT-PCR analysis
for expression of Vezf1. Results are normalized to expression of 18S (18S ribosomal
RNA). *P< 0.05, ***P< 0.001 by Student’s T-test. Data are presented as mean§SD.
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results in a decrease in the number of ventricular cardiomyocytes at
4 dpf and inhibits the b-adrenergic stress-induced increase in the
amount of cardiomyocytes (Fig. 3E). Vezf1 knockdown also results in
reduced cardiomyocyte size, or atrophy, at baseline and suppresses
isoprenaline-induced increase in the size of cardiomyocytes (Fig. 3F).
Vezf1 knockdown has no signiﬁcant effect on the amount of apopto-
tic cardiomyocytes at baseline or following 48 h Iso treatment (Fig.
S2). Ultrastructural analysis of Vezf1 KD hearts at 2 dpf does not
show gross abnormalities in myoﬁlament structure. (Fig. S3).3.4. Loss of Vezf1 impairs cardiac contractile response to b-adrenergic
stimuli
Cardiac function in zebraﬁsh was analyzed from in vivo video
recordings (Fig. 4A). We found that Vezf1 knockdown decreasesventricular size at 2 dpf and completely abolishes the isoprenaline-
induced increase in ventricular diastolic area at 4 dpf (Fig. 4B). Vezf1
knockdown does not affect cardiac systolic function analyzed at 2 dpf
and 4 dpf, but abrogates the isoprenaline-induced enhancement of
cardiac contractile function at 4 dpf (Fig. 4C and D). Ventricular relax-
ation is prolonged in Vezf1 KD hearts at 2 dpf and Vezf1 knockdown
also inhibits the isoprenaline-induced shortening of the relaxation
time at 4 dpf (Fig. 4E). The defects in isoprenaline-induced ventricular
growth and contractility in Vezf1 KD zebraﬁsh culminate in marked
decrease in both stroke volume and cardiac output compared to con-
trol hearts (Fig. 4F and G). Injection of capped Vezf1 RNA results in
full or partial rescue of the phenotype induced by Vezf1 knockdown
(Fig. 4BG). We then performed Ca2+ imaging on 3 dpf isolated zebra-
ﬁsh hearts using Fura2 as calcium indicator. We found Vezf1 KD and
control MO ventricles to show similar resting Ca2+ concentration, Ca2
+ transient amplitude, and Ca2+ transient decay time (Fig. 4H). No sig-
niﬁcant arrhythmias were observed.
3.5. Vezf1 is expressed in adult cardiomyocytes and regulates
cardiomyocyte growth and shortening
We thus observed that Vezf1 knockdown in zebraﬁsh resulted in
reduced cardiac growth and lack of contractile response to b-adren-
ergic stress, whereas no difference was observed in Ca2+ kinetics. This
prompted us to investigate if Vezf1 could serve a direct role in cardio-
myocytes. Data derived from studies of embryonic mouse tissues sug-
gest that Vezf1 is primarily expressed in endothelial cells [8]. To
investigate if Vezf1 is expressed in adult cardiomyocytes, we frac-
tioned resident cardiac cells from adult mouse myocardium to obtain
endothelial cell, ﬁbroblast and cardiomyocyte fractions. qRT-PCR
analysis for expression of eNOS, Col1A1 and a-MHC indicated high
purity of fractioned endothelial cells, ﬁbroblasts and cardiomyocytes,
respectively (Fig. 5A). qRT-PCR analysis for Vezf1 in resident cardiac
cells shows that Vezf1 is expressed equally in all three resident car-
diac cell types (Fig. 5B).
To study the biological function of Vezf1 in cardiomyocytes, we
depleted Vezf1 in adult rat ventricular cardiomyocytes by RNAi,
which resulted in 70% decrease in Vezf1 mRNA level compared to the
control siRNA treated cells (Fig. 5C, p < 0.0001). Microscopy analysis
of cardiomyocyte size shows that depletion of Vezf1 by two different
siRNAs signiﬁcantly attenuates isoprenaline-induced increase in car-
diomyocyte size (Fig. 5D). Vezf1 siRNA treated cardiomyocytes also
display signiﬁcantly shorter sarcomere length compared to control
cells after 24 h of isoprenaline treatment (Fig. 5E). We then analyzed
the effect of Vezf1 depletion on Ca2+ handling in isolated cardiomyo-
cytes. Similar to ﬁndings in zebraﬁsh in vivo, Vezf1 knockdown in
adult rat cardiomyocytes has no effect on Ca2+ transient kinetics
(Fig. 5F). However, Vezf1 knockdown signiﬁcantly attenuated cardio-
myocyte shortening (Fig. 5F). While Vezf1 knockdown in zebraﬁsh
did not induce apoptosis at baseline or following hemodynamic
stress, we addressed the role of Vezf1 in regulating cardiomyocyte
viability under hypoxic stress. We found that Vezf1 depletion has no
effect on cardiomyocyte viability in normoxic conditions and analysis
for cardiomyocyte death immediately after 4 h of hypoxia, or after
5 h or 24 h reperfusion shows no difference between the Vezf1 siRNA
and control siRNA treated cells (Fig. S4).
3.6. Vezf1 regulates cardiomyopathy related genes
To identify the molecular targets of Vezf1 in cardiomyocytes, we
performed RNA sequencing analysis of samples from Vezf1 siRNA
treated NRVMs. We found that Vezf1 silencing resulted in signiﬁcant
regulation of 1144 transcripts (FDR < 0.05, ArrayExpress accession
E-MTAB-7124). 28 transcripts were upregulated and 53 transcripts
downregulated by more than 2-fold (FDR < 0.05, Table S2). KEGG
pathway analysis of the differentially expressed genes identiﬁed 14
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6 J. Paavola et al. / EBioMedicine 51 (2020) 102608gene functions including cardiac muscle contraction and dilated car-
diomyopathy. The only pathway signiﬁcantly enriched in Reactome
pathway analysis was muscle contraction. Among the genes most sig-
niﬁcantly regulated by Vezf1, were cardiac muscle contraction and
cardiomyopathy related genes Myh7 (b-MHC), Atp1a2, and Acta1
(Ska) (Table S2). qPCR analysis of RNA samples from NRVMs con-
ﬁrmed that transcription of Myh7 and Atp1a2 were decreased and
Ska mRNA levels were increased in response to Vezf1 knockdown
(Fig. S5). RNA sequencing further showed that a number of MCAT ele-
ment containing genes were signiﬁcantly regulated by Vezf1 in ratcardiomyocytes, including Myh7, Atp1a2, Tcap, Myh11, Cacng7,
Acta1, Tnnc2, MYH6, cardiac troponin T and cardiac troponin C (Table
S2, ArrayExpress accession E-MTAB-7124).
To investigate if Vezf1 knockdown affects stress-induced expres-
sion of cardiomyopathy related genes, we treated NRVMs with iso-
prenaline for 24 h. We found that knockdown of Vezf1 in NRVMs
prevented both basal and isoprenaline induced expression of
b-MHC (Fig. 5G). Vezf1 silencing enhanced isoprenaline-induced
skeletal alpha actin (Acta1, Ska) expression, but had no effect on
either basal or isoprenaline-induced expression of ANP (Fig. 5G).
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Fig. 3. Vezf1 knockdown reduces cardiac growth. Zebraﬁsh were treated with Ctrl
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(Iso) for 48 h from 2 dpf to 4 dpf. Zebraﬁsh hearts were stained with Mef-2 antibody
(red) to identify cardiomyocyte nuclei and with ZN-5 antibody (green) to delineate car-
diomyocyte cell borders. (AD) Representative images of hearts of zebraﬁsh treated
with Ctrl MO, Vezf1 MO, Ctrl MO + Iso and Vezf1 MO + Iso. The ventricle is marked
with an arrow. Scale bar: 25 mm. (E) Analysis for cardiomyocyte number and (F) The
area of ventricular cardiomyocytes. n = 9 for each group. *P < 0.05, ***P < 0.001. Data
are presented as mean § SD.
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foundly decreased in Vezf1 depleted cardiomyocytes (Fig. 5G). To
investigate whether Vezf1 depletion similarly affects protein levels of
its target genes, NRVMs were transfected with an siRNA targeting a
distinct site in Vezf1 mRNA, and the cells were stimulated with phen-
ylephrine or basic ﬁbroblast growth factor for 48 h. Western blot
analysis of protein samples shows that Vezf1 siRNA decreased both
basal and hypertrophic stimuli-induced b-MHC protein levels
(Fig. 5H). In agreement with the mRNA data, Vezf1 knockdown
resulted in an increase in Ska protein levels, but only had a modest
effect on basal or hypertrophic agonist-induced ANP levels (Fig. 5H).
Similar to mRNA data, Vezf1 silencing resulted in a signiﬁcant reduc-
tion in b-MHC/Ska ratio at protein level (Fig. 5I).To investigate whether Vezf1 targets the same genes in zebraﬁsh,
qPCR analysis of zebraﬁsh samples at 1 dpf showed that Vezf1 knock-
down decreased expression of vMHC (zebraﬁsh orthologue for
b-MHC) by 92% compared to controls (Fig. S6). Expression of Ska, on
the other hand, was signiﬁcantly increased in Vezf1 KD zebraﬁsh
hearts (Fig. S6). Consequently, the vMHC/Ska mRNA ratio was dimin-
ished in hearts of Vezf1 KD zebraﬁsh (Fig. S6).
3.7. Vezf1 regulates b-MHC promoter luciferase reporter
To evaluate if Vezf1 regulates b-MHC promoter activity, NRVMs
were co-transfected with ﬁve different b-MHC promoter luciferase
reporter constructs (171 to 3500 bp) together with Vezf1 siRNA
or control siRNA. We found that Vezf1 siRNA treatment decreases the
relative luciferase activity of b-MHC promoters by 5280% with the
most pronounced effect in the 408 b-MHC reporter construct
(Fig. 6A). The ﬁve b-MHC promoter luciferase reporter constructs
(171 to 3500 bp) were then co-transfected with mouse Vezf1
plasmids or empty pGL3basic plasmids. We found that overexpres-
sion of Vezf1 leads to a signiﬁcant increase in the activity of the 914
b-MHC and 3500 b-MHC promoter luciferase constructs (Fig. S7).
Overexpression of Vezf1 also results in an increase in cardiomyocyte
size and augments b-MHC expression, but that did not reach signiﬁ-
cance (Fig. S7).
3.8. Vezf1 targets an MACT binding site within the b-MHC promoter and
interacts with TEAD-1
To investigate the mechanism by which Vezf1 regulates b-MHC
gene expression, we performed mutational analysis of the 408
b-MHC promoter construct. As RNA sequencing identiﬁed a number
of genes with MCAT binding sites regulated by Vezf1, we utilized two
408 b-MHC promoter constructs with MCAT site mutations (Dbe2
and Dbe3) [26,27]. In addition, a 408 b-MHC promoter construct
with mutation of a constitutive repressive site was utilized (Dbe1)
[27]. The activities of the mutated 408 b-MHC promoter constructs
were then investigated in control siRNA and Vezf1 siRNA treated
NRVMs. In control siRNA treated NRVMs, the Dbe1 construct shows
90% increase in activity compared to the wild-type 408 b-MHC pro-
moter construct (Fig. 6B), whereas the Dbe2 and Dbe3 constructs
show 4050% decrease in luciferase activity. In Vezf1 siRNA treated
NRVMs, responses to Dbe1 and Dbe2 mutations are similar to those
of control siRNA treated cells (Fig. 6C). However, unlike control siRNA
treated cells, the mutation of an MCAT binding site at 211 to 189
(Dbe3) has no effect in Vezf1 silenced cells. These data thus indicate
that Vezf1 targets the be3 site of the b-MHC promoter. Comparisons
of the relative responses to the 408 b-MHC promoter mutations in
control siRNA and Vezf1 siRNA treated cells are shown in Fig. 6D.
MCAT motifs in the Myh7 gene are binding sites for transcriptional
enhancer factors (TEADs/TEFs) [28]. To investigate whether Vezf1
regulation of Myh7 involves binding of Vezf1 to TEFs, we immuno-
precipitated rat LV lysates with Vezf1 antibody and analyzed for co-
immunoprecipitation of TEF factors. We found that Vezf1 binds
TEAD-1 in hearts in vivo (Fig. 6E). The speciﬁcity of the 40 kD TEAD-1
band was further conﬁrmed by knockdown of TEAD-1 with two dif-
ferent siRNAs in neonatal rat cardiomyocytes (Fig. 6F).
4. Discussion
Vezf1 has previously been associated with regulation of endothe-
lial cell function. However, the role of Vezf1 in cardiac biology
remains unknown. In the current study, we found that Vezf1 expres-
sion is decreased in LV samples of patients with idiopathic and ische-
mic cardiomyopathy, and in mice subjected to experimental MI.
Studies in zebraﬁsh show that Vezf1 is necessary for isoprenaline-
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Fig. 4. Loss of Vezf1 impairs cardiac contractile response to b-adrenergic stimuli. Zebraﬁsh were treated with Ctrl morpholino (MO), Vezf1 MO or Vezf1 MO together with capped
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tricular systolic function. Analysis of cardiac tissues showed that
Vezf1 knockdown decreases cardiomyocyte size, but does not affect
cardiomyocyte viability. In agreement with ﬁndings in zebraﬁsh,
Vezf1 depletion in isolated cardiomyocytes has no effect on cardio-
myocyte viability, but decreases cardiomyocyte shortening and cardi-
omyocyte growth in response to isoprenaline. The defective
contractile response to isoprenaline stimuli in zebraﬁsh prompted us
to investigate if Vezf1 knockdown affects Ca2+ cycling. However,Vezf1 knockdown either in zebraﬁsh or in isolated cardiomyocytes
did not affect Ca2+ transient kinetics.
Analysis for Vezf1 target genes identiﬁed Myh7 as a key regula-
tory target in cardiomyocytes and this was further conﬁrmed with a
notable reduction in Myh7/b-MHC expression at the protein level.
Strikingly, analysis for zebraﬁsh ventricular MHC (vMHC) expression
at 1 dpf (when Vezf1 deletion had not yet induced a cardiac pheno-
type) showed 92% reduction in vMHC expression. In zebraﬁsh, vMHC
is the likely orthologue of the mammalian b-MHC/Myh7, with its
Fig. 5. Vezf1 is expressed in adult cardiomyocytes and regulates cardiomyocyte growth and cardiomyopathy related genes. (A) qRT-PCR analysis of the expression of endothelial
nitric oxide synthase (eNOS), collagen type I alpha 1 chain (Col1a1), and a myosin heavy chain 6 (a-MHC) mRNAs in pools of fractionated resident mouse cardiac cells. eNOS,
Col1a1 and a-MHC were used as markers for endothelial cells (Endo), ﬁbroblasts (Fibro), and cardiomyocytes (Myo), respectively. n = 5. (B) qPCR analysis of Vezf1 mRNA levels in
cardiomyocytes and ﬁbroblasts relative to that in the endothelial cells. n = 5. (C) Adult rat ventricular cardiomyocytes were transfected with Vezf1 siRNA (100 nM) or Control siRNA
(100 nM) and 3 days later RNA samples were collected. Shown is qRT-PCR analysis for expression of Vezf1. Results are normalized to expression of 18S (18S ribosomal RNA). n = 6.
(D and E) Adult rat ventricular cardiomyocytes were transfected with two distinct Vezf1 siRNAs (100 nM) or Control siRNA (100 nM) and 1 day later cells were stimulated with iso-
prenaline (Iso, 1mM) for 48 h where indicated. (D) Shown is microscopy analysis for cardiomyocyte size. Ctrl siRNA n = 8, Vezf1 A siRNA n = 9, Vezf1 B siRNA n = 10; Ctrl siRNA + Iso
n = 10, Vezf1 A siRNA + Iso n = 15, Vezf1 B siRNA + Iso n = 13. (E) Shown is microscopy analysis for sarcomere length (mm). Ctrl siRNA n = 14, Vezf1 B siRNA n = 18; Ctrl siRNA + Iso
n = 22, Vezf1 B siRNA + Iso n = 25. (F) Adult rat ventricular cardiomyocytes were transfected with Vezf1 siRNA (100 nM) or control siRNA and 3 days later Ca2+ cycling and cardio-
myocyte (CM) shortening were analyzed. Ctrl n = 44, Vezf1 siRNA n = 43. (G) Neonatal rat ventricular cardiomyocytes were transfected with Vezf1 siRNA (100 nM) or control siRNA
and 2 days later cells were treated with Iso (1mM) for 24 h. Shown is qRT-PCR analysis for expression of Vezf1, b-MHC (myosin heavy chain beta-subunit), Ska (skeletal alpha actin),
ANP (atrial natriuretic peptide) and b-MHC versus Ska ratio. Results are normalized to expression of 18S (18S ribosomal RNA). n = 4. (H-I) Neonatal rat ventricular cardiomyocytes
were transfected with Vezf1 siRNA (100 nM) or control siRNA (100 nM) and 3 days later cells were treated with either vehicle, phenylephrine (PE, 100 mM) or basic ﬁbroblast
growth factor (FGF, 20 ng/ml) for 48 h. (H) Shown is immunoblot analysis for b-MHC, ANP, GAPDH, Ska and Vinculin. (I) Shown is b-MHC versus Ska ratio from immunoblot quanti-
ﬁcation. n = 4. *P < 0.05, **P< 0.01, ***P< 0.001. Data are presented as mean § SD.
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Fig. 6. Vezf1 targets an MCAT binding site within b-MHC promoter and interacts with TEAD-1. (A) Neonatal rat ventricular cardiomyocytes (NRVMs) were transfected with b-MHC
promoter (171 to 3500 bp) luciferase reporter constructs together with Vezf1 siRNA (100 nM) or control siRNA (100 nM). 3 days later, relative luciferase activities were analyzed.
Fireﬂy luciferase activities were normalized to renilla luciferase activity and expressed as relative to the activity of respective b-MHC promoter luciferase construct treated with
control siRNA. n = 4. (BD) NRVMs were transfected with an intact 408 b-MHC promoter construct or with 408 b-MHC promoter construct containing either Dbe1, Dbe2 or
Dbe3 mutation together with (B) control siRNA (100 nM) (n = 68) or (C) Vezf1 siRNA (100 nM) (n = 37). 3 days later, relative luciferase activities of the different lengths of
b-MHC promoter constructs were analyzed. Fireﬂy luciferase activities were normalized to renilla luciferase and the data are expressed as relative to that of the wild-type 408
b-MHC promoter construct activity. (D) Comparison of relative change in luciferase activity of 408 b-MHC Dbe1, Dbe2 or Dbe3 promoter construct to that of wild-type 408
b-MHC promoter luciferase construct in control siRNA and Vezf1 siRNA treated cells. n = 38. (E) Adult rat left ventricular (LV) tissue samples were immunoprecipitated with Vezf1
antibody or control IgG. Shown is immunoblot analysis for Transcription enhancer factor-1 (TEAD-1) in immunoprecipitates and LV lysates. (F) NRVMs were transfected with two
distinct TEAD-1 siRNAs (100 nM) or control siRNA (100 nM) and 3 days later protein samples were collected. Shown is immunoblot analysis for TEAD-1 in rat LV lysates and in
NRVMs. *P < 0.05, **P < 0.01, ***P < 0.001. Data are presented as mean § SD.
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J. Paavola et al. / EBioMedicine 51 (2020) 102608 11similar ventricle-speciﬁc expression pattern [29]. Myosin is the main
component of the sarcomere thick ﬁlament and the intrinsic ATPase
activity of the myosin heavy chains transduces chemical energy into
mechanical energy resulting in cell contraction. The two major car-
diac MHC genes, a-MHC (Myh6) and b-MHC, have been shown to be
reciprocally regulated during development and during cardiac
pathologies [30]. Notably, in the current study the robust decrease in
Myh7 expression in response to Vezf1 knockdown in cardiomyocytes
was not associated with upregulation of Myh6 expression that could
rescue the total MHC levels. Instead, we found that expression of thin
ﬁlament skeletal a-actin (Ska) was increased in Vezf1 KD hearts and
Vezf1 silenced cardiomyocytes resulting in a robust decrease in the
myosin/actin ratio. Normal myosin/actin ratio in the myocardium is
1.0/4.1 [31] and maintenance of the structure and function of cardiac
muscle requires precise control of the synthesis, assembly, and turn-
over of the sarcomere proteins [32]. Previously, reduction in myosin/
actin ratio has been observed in pulmonary artery hypertension
patients, who have reduced LV ejection fraction and reduced LV car-
diomyocyte size [33]. The decrease in myosin/actin ratio did not
result in ventricular dysfunction in unstressed Vezf1 KD hearts,
which is likely due to substantial contractile reserve (the difference
between myocardial contractility in response to stress compared to
contractility at rest) of the myocardium. However, the disturbed pro-
tein balance in the cardiomyocyte contractile unit provides a poten-
tial mechanism for the defective contractile response of Vezf1 KD
hearts during hemodynamic stress.
RNA sequencing analysis revealed that the highest regulated genes
were ones containing a muscle-speciﬁc MCAT element in their regula-
tory regions, such as b-MHC (Myh7), Atp1a2, Tcap, Myh11 and Ska
(Acta1) that were all regulated by more than log 2 fold. Prior data
shows that MCAT motifs (binding sites for TEAD/TEF transcription fac-
tors) in the Myh7 gene are essential for Myh7 gene expression [28]. By
using mutational analysis, we demonstrate that an MCAT element in
the Myh7 promoter at least partially mediates the transcriptional
response to Vezf1 knockdown. However, the proximal promoter
region of Myh7 does not contain putative binding sites for Vezf1. Inter-
estingly, cardiomyocyte knockdown of TEAD-1 in neonatal mice in
vivo has been shown to profoundly augment Ska expression and
decrease Myh7 expression [34]. Tamoxifen inducible cardiomyocyte-
speciﬁc knockdown of TEAD-1 in the adult mice resulted in dilated
cardiomyopathy and signiﬁcant reduction in Myh7 expression [35].
Moreover, overexpression of TEAD-1 was sufﬁcient to enhance Myh7
expression [36]. In the current study, analysis for Vezf1 binding part-
ners showed that Vezf1 co-immunoprecipitates with TEAD-1 in hearts
in vivo. In addition, Vezf1 shares common downstream target genes
with TEAD-1. However, differently from TEAD-1 overexpression [36],
Vezf1 overexpression is not sufﬁcient to drive Myh7 expression.
Previous data have shown that Vezf1 has a central role in vasculo-
genesis and angiogenesis [10,12]. In agreement, we observed that
Vezf1 knockdown in zebraﬁsh resulted in altered formation of the
two major trunk axial vessels and increased distance between inter-
segmental vessels following b-adrenergic stress. Endothelial cell
Vezf1 is a positive regulator of endothelin-1 (ET-1) [11], which is
known to induce cardiac hypertrophy, enhance cardiac contractile
function, and regulate cardiomyocyte Ca2+ homeostasis [3739]. We
cannot thus rule out that Vezf1-mediated regulation of endothelial
cell -derived factors, such as ET-1, may have had effect on the
observed cardiac phenotype, such as reduced cardiac growth in the
zebraﬁsh [40]. However, we found that Vezf1 is expressed in adult
cardiomyocytes in levels comparable to that in endothelial cells, and
directly regulates expression of cardiac genes. Lack of targeting Vezf1
in the adult heart is a limitation of the current study. In future studies,
it would be of interest to determine the role of Vezf1 in the stressed
myocardium by targeting Vezf1 in cardiomyocytes. Interestingly, a
different set of genes was regulated by Vezf1 in cardiomyocytes com-
pared to that previously described in endothelial cells [12].Interaction of Vezf1 with TEAD-1 actually indicates that cell type-
speciﬁc transcriptional cofactors participate in Vezf1-mediated tran-
scriptional regulation.
In summary, our data shows that in addition to regulating angio-
genesis, Vezf1 is expressed in cardiomyocytes and directly regulates
genes involved in cardiac contractile function and dilated cardiomy-
opathy. We further ﬁnd that zebraﬁsh Vezf1 is necessary for hemody-
namic stress-induced increase in cardiac contractile function and loss
of Vezf1 results in greater propensity towards heart failure. Molecular
analysis for Vezf1 function in cardiomyocytes identiﬁes TEAD-1 as a
binding partner of Vezf1. These data thus identify previously unap-
preciated biological functions for Vezf1 in cardiomyocytes. However,
further studies are needed to evaluate the signiﬁcance of decreased
Vezf1 expression in diseased human myocardium and to understand
cell type-speciﬁc effects of Vezf1 in the adult heart.
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